Your Market Research Library
 

Ask For A FREE Membership Here !
 


Your Market Research starts at Allbizreport !
Order here all your market reports, company profiles, country analysis, competitive intelligence ... upon any industries and countries :
20.000 market research, 5.000 company profiles, 150 industry monitor

   
  
   
   
   Advanced Search     

   
  
   
  
   
   


Home

Electricity in Canada
Market Briefing, September 2007, 200  €


Description

Datamonitor's Electricity in Canada industry profile is an essential resource for top-level data and analysis covering the electricity industry.
It includes detailed data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies and demographic information.
Scope * Contains an executive summary and data on value, volume and/or segmentation* Provides textual analysis of the industry’s recent performance and future prospects* Incorporates in-depth five forces competitive environment analysis and scorecards * Includes a five-year forecast of the industry* The leading companies are profiled with supporting key financial metrics * Supported by the key macroeconomic and demographic data affecting the market Highlights * Detailed information is included on market size, measured by value and/or volume* Five forces scorecards provide an accessible yet in depth view of the market’s competitive landscape * Market shares are covered by manufacturer or brand Why you should buy this report * Spot future trends and developments * Inform your business decisions * Add weight to presentations and marketing materials * Save time carrying out entry-level researchMarket DefinitionThe electricity market consists of the sale of electricity to industrial, commercial, household and other end-users, including agricultural and transport users.
The volume of the market is calculated as the total volume of electricity consumed (in billions of kilowatt hours, kWh), and the market value has been calculated according to average annual electricity prices.
Note that 1 TWh is identical to 1 billion kWh.
Any currency conversions used in the creation of this report have been calculated using constant 2006 annual average exchange rates.
For the purpose of this report the Americas comprises Brazil, Canada, Mexico and the US.

Sommaire
 
TABLE OF CONTENTS
EXECUTIVE SUMMARY 3
CHAPTER 1 Market Overview 7
1.1 Market Definition 7
1.2 Research Highlights 7
1.3 Market Analysis 8
CHAPTER 2 Market Value 9
CHAPTER 3 Market Volume 10
CHAPTER 4 Market Segmentation I 11
CHAPTER 5 Market Segmentation II 12
CHAPTER 6 Market Share 13
CHAPTER 7 Five Forces Analysis 14
7.1 Summary 14
7.2 Buyer Power 15
7.3 Supplier Power 16
7.4 New Entrants 17
7.5 Substitutes 18
7.6 Rivalry 19
CHAPTER 8 Leading Companies 20
8.1 Hydro-Quebec 20
8.2 TransAlta Corporation 22
8.3 Ontario Power Generation Inc. 24
CHAPTER 9 Market Forecasts 26
9.1 Market Value Forecast 26
9.2 Market Volume Forecast 27
CHAPTER 10 Macroeconomic Indicators 28
CHAPTER 11 Appendix 30
11.1 Methodology 30
11.2 Industry Associations 31
11.3 Related Datamonitor Research 31

LIST OF TABLES
Table 1: Canada Electricity Market Value: $ billion, 2002-2006 9
Table 2: Canada Electricity Market Volume: TWh, 2002-2006 10
Table 3: Canada Electricity Market Segmentation I: % Share, by Value, 2006 11
Table 4: Canada Electricity Market Segmentation II: % Share, by Value, 2006 12
Table 5: Canada Electricity Market Share: % Share, by Volume, 2006 13
Table 6: Key Facts: Hydro-Quebec 20
Table 7: Key Financials: Hydro-Quebec 21
Table 8: Key Facts: TransAlta Corporation 22
Table 9: Key Financials: TransAlta Corporation 23
Table 10: Key Facts: Ontario Power Generation Inc. 24
Table 11: Key Financials: Ontario Power Generation Inc. 25
Table 12: Canada Electricity Market Value Forecast: $ billion, 2006-2011 26
Table 13: Canada Electricity Market Volume Forecast: TWh, 2006-2011 27
Table 14: Canada Size of Population (million) , 2002-2006 28
Table 15: Canada GDP (1995=100), 2002-2006 28
Table 16: Canada Inflation, 2002-2006 28
Table 17: Canada Exchange Rate, 2002-2006 29

Table of Contents
Innovations in Cardiovascular Disease Management
Executive Summary 10
The Management of Cardiovascular Disease 10
Cardiovascular and Interventional Procedures 11
Emerging Coronary Stents and Stent Systems 12
Innovations in Minimally Invasive Cardiac Surgery 13
Cardiovascular Drugs in Early Stage Development 14
New and Emerging Cardiovascular Drugs 14
Chapter 1 The Management of
Cardiovascular Disease 18
Summary 18
Introduction 19
The Global Burden of Cardiovascular Disease 19
CVD remains the leading cause of death in the United States 19
CVD Rates in Central and Eastern Europe 21
Noncommunicable Diseases in the Developing World 21
Background to the Major Cardiovascular Conditions 23
Coronary Artery Disease (CAD) 23
Atherosclerosis 23
Angina Pectoris 25
Acute Myocardial Infarction (MI) 27
Heart Valve Disorders 29
Aortic heart valve 29
Mitral Valve Disease 30
Pulmonary Valve Disease 32
Tricuspid Valve Disease 32
High Blood Pressure: Hypertension 32
Heart Rhythm Disorders (Heart Arrhythmia) 33
Peripheral Vascular Disease 35
Peripheral Artery Disease (PAD) 35
Peripheral Venous Disorders (PVD) 37
Stroke or Cerebrovascular Accidents (CVA) 38
Ischaemic Stroke 38
Haemorrhagic stroke 38
Chapter 2 Latest Developments in
Cardiovascular and PCI
Procedures 42
Summary 42
Introduction to Percutaneous Coronary Interventions 43
Indications for PCI 44
PCI Procedural Volumes 44
PCI Used Primarily to Treat Unstable Angina and acute ST-elevation MI 45
Inter-country Variance in PCI Procedural Rates 46
China and India: Huge growth potential and market development 47
Latest Developments in PCI Procedures 49
Embolic Protection Devices 49
Current Products 50
Development Stage Products and Current Status 55
Future Technologies and Trends 58
Coronary Atherectomy 59
Rotational Coronary Atherectomy (Rotoblation) 59
Directional Coronary Atherectomy (DCA) 59
Orbital Atherectomy 60
Ablative laser-assisted angioplasty 60
Chapter 3 Emerging Coronary Stents and
Stent Systems 64
Summary 64
Emerging Coronary Stents and Stent Systems 65
Key Events 65
Introduction of Drug-Eluting Stents (DES) 67
Development of Drug-Eluting Stents 70
Sirolimus (Rapamycin) 70
Paclitaxel 71
Tacrolimus 72
Everolimus (RAD-001) 73
Zotarolimus (also called ABT-578) 73
DES – Recent News, Product Developments and Clinical Trial Updates 74
Market Developments and Forecasts for Drug-Eluting Stents 77
Emergence of Bioabsorbable Stents 82
Biomaterials and Bioabsorbable Polymers 83
Further Coronary Stent Developments and Technological Trends 85
Novel Coating Technologies 85
Gene Therapy technologies and its Potential Use to Prevent Restenosis 86
Coronary Stents and Endothelial Progenitor Cells (EPCs) 87
Nanotechnologies and Drug-Eluting Coronary Stents 88
Development of Novel Estradiol Containing Drug-Eluting Stents 88
Stem-Cell Derived Endovascular Cells 89
Chapter 4 Innovations in Minimally Invasive
Cardiac Surgery (MICS) 92
Summary 92
Introduction 93
Minimally Invasive Direct Coronary Artery Bypass (MID-CAB) 93
Indications for MIDCAB 94
Off-Pump Coronary Artery Bypass (OP-CAB) 94
Indications for OP-CAB 94
Minimally Invasive Port Access 95
Indications for Minimally Invasive Port Access 96
Robotic Assisted Coronary Artery Bypass (RA-CAB) 96
Current and Emerging Technologies 98
Robotics in Minimally Invasive Cardiac Surgery 98
Robotic Systems 98
Computer Aided Cardiac Surgery 100
Virtual Reality in Cardiac Surgery 100
Laser Heart Surgery or transmyocardial Laser revascularization (TMLR) 101
The CO2 Heart Laser System 101
The holmium:YAG (yttrium aluminium garnet) laser 102
The excimer laser 102
Chapter 5 Cardiovascular Drugs in Early
Stage Development 106
Summary 106
Introduction 107
Early Developments in Key Cardiovascular Disease Classes 107
Angina 107
Arrhythmiasis 110
Atherosclerosis 112
Atrial Fibrillation 115
Congestive Heart Failure 116
Hypercholesterolemia 118
Hypertension 120
Myocardial Infarction 122
Thrombosis 124
Chapter 6 New and Emerging
Cardiovascular Drugs 128
Summary 128
Introduction 129
Anti-Hypertensives 129
Tekturna (Aliskiren) 130
Development of a New Class of Renin Inhibitors 132
Exforge (valsartan plus amlodipine) 133
CHF-1521 134
Cleviprex(TM) (Clevidipine) 135
Antihypertensives: Current Pipeline and Late Stage Development 136
Cardoxal (MC-4232) (MC-1 cardioprotectant plus lisinopril) 138
Darusentan 139
Ambrisentan 139
Nebivolol 140
Zanipress® / Zanitek® 140
Thelin™ (Sitaxsentan) 141
TBC3711 142
Anti-Dyslipidemics 143
Pfizer discontinues torcetrapib development 144
R1658 145
Simcor (Niaspan® (extended-release niacin) and simvastatin (generic
Zocor®)) 145
CRESTOR® (rosuvastatin) and CRESTOR/ABT-335 combination 147
Synordia 149
Lapaquistat (TAK-475) 150
SLx-4090 151
AEGR-733 152
Compound Number 256073 and 501516 153
LBM642 153
Dyslipidaemia: Current Pipeline and Late Stage Development 154
Anti-Thrombotics 156
Rivaroxaban (BAY59-7939) 156
Rendix (dabigatran etexilate, BIBR-1048) 157
Idraparinux 157
Apixaban 158
SSR-126517 158
Exanta/ximelagatran 159
Anti-Thrombotics: Current Pipeline and Late Stage Development 160
Anti-Arrhythmics 161
Stedicor (Azimilide) 163
Multaq (Dronedarone) 164
Vernakalalant (RSD 1235) 165
Tecadenoson CVT510 167
Pulzium IV (Tedisamil) 167
Anti-Arrhythmics: Current Pipeline and Late Stage Development 168
Chapter 7 Appendix 170
Methodology Statement 170
Primary Data and Information Gathering 170
Secondary Data and Information Gathering 170
Market Share Analysis and Market Forecast Predictions 171
Glossary 173
Index 182
List of Figures
Figure 1.1: Breakdown of Deaths from Cardiovascular Diseases, USA 2002 20
Figure 1.2: Leading causes of death in developing countries, 2002 23
Figure 2.3: Use of Percutaneous Coronary Intervention in Europe, 2005 46
Figure 3.4: Estimated number of Stent Procedures (BMS & DES) % Total Number of PTCA
Procedures 69
Figure 3.5: Actual and projected revenues from Coronary Stents, Worldwide sales- 2006 81
Figure 3.6: Market Share Analysis, DES v BMS World, 2006 82
List of Tables
Table 1.1: Age- and gender-specific incidence of recognised MI 28
Table 1.2: Age- and gender-specific incidence of unrecognised MI 28
Table 2.3: Estimated volume of cardiovascular procedures by region (US 2002) 45
Table 2.4: PCI procedure rates in Selected Countries, 2005 49
Table 5.5: Selected Early Stage Anti Anginal Drug Developments 108
Table 5.6: Selected Early Stage Anti Arrhythmiasis Drug Developments 110
Table 5.7: Selected Early Stage Atherosclerosis Drug Developments 112
Table 5.8: Selected Early Stage Atrial Fibrillation Drug Developments 115
Table 5.9: Selected Early Stage Congestive Heart Failure Drug Developments 116
Table 5.10: Selected Early Stage Hypercholesterolemia Drug Developments 118
Table 5.11: Selected Early Stage Hypertension Drug Developments 120
Table 5.12: Selected Early Stage Myocardial Infarction Drug Developments 122
Table 5.13: Selected Early Stage Thrombosis Drug Developments 125
Table 6.14: Characteristics of Major Classes of Lipoproteins 144
Table 6.15: AstraZeneca’s Current Anti-Dyslipidaemia Pipeline 149
Table 6.16: Classification of Anti-Arrhythmics 162

Table of Contents
The Future of Ethical Food and Drinks
Executive Summary 10
Key drivers of ethical food and drinks 10
Ethical food and drinks market development 11
Innovation and NPD in ethical food and drinks 12
Industry survey 13
Conclusions and future development 14
Chapter 1 Ethical initiatives in food and
drinks 16
Introduction 16
Key initiatives 17
Trading fairly with developing countries 17
Sustainability 19
Food safety 20
Animal welfare 21
Packaging, pollution and the environment 21
Chapter 2 Key drivers of ethical food and
drinks 24
Summary 24
Introduction 25
Consumer demand for ethical products 25
Purchasing ethical products and ethical issues 26
Organic food and drink consumers 31
Supply-side drivers of ethical food and drink 34
Ethical private label 34
Private label Fairtrade 36
The importance of certifiers 38
Packaging and the environment 40
Growing pressure to reduce packaging 40
Pollution 42
Packaging, pollution and ethical food and drink marketing 43
Chapter 3 Ethical food and drink market
development 46
Summary 46
Introduction 47
Fairtrade products 47
Coffee still dominates the Fairtrade market 50
The overlap between Fairtrade and organic 54
Organic food and drink 54
Key sectors of the organic market 56
Ethical becomes mainstream 57
Current and future market penetration of Fairtrade 58
Organic moves into the mainstream 60
Chapter 4 Innovation and NPD in ethical
food and drinks 64
Summary 64
Introduction 65
Growth in new ethical product launches 65
Category analysis 67
Regional analysis 69
Product tag analysis 72
Ethical claims 74
Ethical NPD 76
Organic 78
Fairtrade 79
Local sourcing 85
No added hormones and no antibiotics 87
No genetic modification 90
No additives 92
Ethical packaging 93
Recycled materials 96
Reduced packaging 98
Biodegradable packaging 99
Chapter 5 Industry survey 104
Summary 104
Introduction 105
Driving the uptake of ethical food and drink 105
Consumer attitudes 105
Key influencers 107
Retailer initiatives 108
Manufacturer initiatives 111
Key features 112
Price premiums of ethical products 114
Leading categories and regions 116
Key categories 116
Leading regions 118
Company strategy 119
Development strategies 119
Leading company types 120
Leading ethical brands 122
Chapter 6 Conclusions and future
development 126
Summary 126
Introduction 127
Ethical initiatives SWOT analysis 127
Consumer demand 128
Ethical product marketing 128
Towards a wider ethical remit 129
Investment in the ethical sector 130
Growing use of ethical labels 131
Acquisition of ethical brands 132
Index 134
List of Figures
Figure 1.1: Ethical initiatives in food and drink 16
Figure 1.2: Fairtrade badges in Europe and the US 18
Figure 1.3: Rainforest Alliance certification 18
Figure 1.4: Marine Stewardship Council Blue Ecolabel 20
Figure 2.5: Choosing natural organic food and drinks rather than standard variants over the past
year, by household income, 2006 33
Figure 2.6: Ethical private label development 35
Figure 2.7: Carbon Label use by Innocent Smoothies 43
Figure 3.8: Fairtrade expenditure and growth by country, 2001-2006 49
Figure 3.9: Fairtrade growth by product sector, Europe and North America, 2001-2006 50
Figure 3.10: % share of total category sales that are organic, Europe and US, 2000-2010 57
Figure 4.11: % growth in ethical products launched by category, 2005-2007 66
Figure 4.12: % share of ethical food and drinks launched by category, 2005 and 2007 67
Figure 4.13: % of food and drinks products in each category launched that are ethical, 2005 and
2007 69
Figure 4.14: % share of ethical products launched, by region, 2005 and 2007 70
Figure 4.15: % share of ethical products launched by claim, 2005 and 2007 74
Figure 4.16: % share of products that make the organic claim on other ethical products launched,
2007 76
Figure 4.17: % share of organic & Fairtrade food and drinks launched by category, 2005 and 2007
77
Figure 4.18: Knorr Bio Gemüse, Lidl Fairglobe Café del Mundo and Carrefour AGIR Bio tea 79
Figure 4.19: Sainsbury’s So Organic Fairtrade Chocolate and Trader Joe’s Organic Fair Trade
Breakfast Blend Coffee 80
Figure 4.20: Nescafé Partners’ Blend and Ben & Jerrys Vanilla Fairtrade ice cream 81
Figure 4.21: Ethichoco mousse cake, Nature’s Path Organic Toaster Pastries and Doves Farm
Fairtrade cereal bars 82
Figure 4.22: EcoNugenics MycoKidz and Steaz Energy Organic Fuel 83
Figure 4.23: Bart Fairtrade and Equal Exchange cranberries 84
Figure 4.24: Eat Local and Little Bug Baby Food 86
Figure 4.25: Ben & Jerry's milkshakes, Oh Boy! Oberto Organic Beef Jerky and Campbell's
Organic Chicken Broth 88
Figure 4.26: Earth's Best Sesame Street Ravioli and Tegel Ready to Grill 89
Figure 4.27: Odwalla Choco-Walla and Blue Band Soja Halvarine 91
Figure 4.28: % share of food and drinks launched that make ethical packaging claims by category,
2005 and 2007 95
Figure 4.29: Love Body and Chips Ahoy! 97
Figure 4.30: Jogurt Danone and Adnams Beer 99
Figure 4.31: Saphara Tea, Numi Organic Iced Tea, Belu water and Annie Chun’s Kung Pao 100
Figure 5.32: The importance of consumer attitudes in driving uptake of ethical food and drink 106
Figure 5.33: The importance of key groups as drivers of the uptake of ethical food and drinks 107
Figure 5.34: The importance of retailer initiatives in changing consumer attitudes towards ethical
products 109
Figure 5.35: The importance of manufacturer initiatives in changing consumer attitudes towards
ethical products 112
Figure 5.36: The importance key features will have on influencing consumers to purchase ethical
products over the next 5 years 113
Figure 5.37: How much of a premium are consumers willing to pay for products with an ethical
positioning? 114
Figure 5.38: The importance of ethical food and drink in key product sectors in the next 5 years
compared to today 116
Figure 5.39: Prevalence of ethical food and drinks by region 118
Figure 5.40: Ethical product development strategies over the next 5 years 119
Figure 5.41: Companies that have the most influence on innovation in ethical food and drinks today
and will have in the next 5 years 121
Figure 6.42: SWOT analysis of ethical initiatives 127
List of Tables
Table 2.1: Buying of ethical or socially-responsible grocery items over the last year, by country,
2006 26
Table 2.2: Buying of ethical or socially-responsible grocery items over the past year, by
generational cohort and country, 2006 27
Table 2.3: Influence on purchasing behavior and awareness of issues regarding food and drink,
2006 29
Table 2.4: Organic food users as % of the total US and European population, 2000-2010 32
Table 2.5: European Fairtrade private label development since 2000 36
Table 3.6: Sales of Fairtrade products by country, €m, 2001-2006 48
Table 3.7: Sales of Fairtrade coffee and other products by country, €m, 2001-2006 51
Table 3.8: Fairtrade market by product type, Europe and North America, 2004 & 2006 52
Table 3.9: Organic market value by country, $bn, 2000-2010 55
Table 3.10: Value of US and European organic food and drink by product category, $bn, 2000-
2010 56
Table 3.11: Fairtrade market forecasts, €m, 2006-2011 59
Table 3.12: Sales by value of organic products as % total national category sales, 2005 60
Table 3.13: Forecast sales by value of organic products as % total national category sales, 2010 62
Table 4.14: Top 10 product tags on ethical food and drinks launched, 2005-2007 72
Table 5.15: Top ten ethical food and drink manufacturers 122
Table 6.16: Key ethical acquisitions since 2000 132
Table of Contents
The Future of Biosimilars
Executive Summary 8
Introduction to biosimilars 8
Market landscape for biosimilars: Europe and USA 9
Emerging market landscape for biosimilars: China and India 10
Competitive landscape 10
Case studies 11
Future trends in biosimilars 12
Chapter 1 Introduction to biosimilars 14
Summary 14
Introduction 15
Biosimilars vs generic pharmaceuticals 16
The nomenclature debate 18
Market opportunities 19
Key trends in biosimilar product development 21
Industry profile 23
Challenges faced by biosimilar developers 27
Pre-marketing hurdles 27
Post-marketing challenges 29
Future trends 30
Chapter 2 Market landscape: Europe and
USA 32
Summary 32
Introduction 33
Features of the EU market for biosimilars 33
Regulatory framework 33
Experience with EU framework 35
National laws 36
Drivers and constraints for biosimilars in the EU market 37
Features of the US market for biosimilars 39
Regulatory framework 39
Follow-on biotech drugs 40
Follow-on biologicals 42
Experience with US regulatory mechanisms 42
Drivers and constraints for biosimilars in the US market 44
Chapter 3 Emerging market landscape for
biosimilars: China and India 48
Summary 48
Introduction 49
Features of the Chinese market for biosimilars 50
Regulatory framework 50
Biopharmaceutical market 52
Biopharmaceutical industry 53
Features of the Indian market for biosimilars 57
Regulatory framework 57
Biopharmaceutical industry 58
Conclusion 64
Chapter 4 Competitive landscape 66
Summary 66
Introduction 67
Leading biosimilars players 68
Teva 68
Sandoz 70
Barr/Pliva 72
Biopartners/Bioton 74
Stada/Bioceuticals 76
BioGeneriX/ratiopharm 78
Niche players 79
CoGenesys 79
Maxygen 80
Viropro 81
Trends in the biosimilars industry 82
Chapter 5 Case studies 86
Summary 86
Introduction 87
Sandoz' Omnitrope: a regulatory saga 88
Comparison of EU approval routes for Omnitrope and Valtropin 89
Conclusions 89
Targeting superbiosimilars: Neose Technologies 91
EPO market 92
G-CSF market 94
Conclusions 95
Taking developed products to market: SciGen 96
Manufacturing risks 97
Marketing strategy 98
Pipeline growth 99
Conclusions 100
Chapter 6 Future trends in biosimilars 102
Summary 102
Introduction 103
Main product opportunities 104
Product development issues 106
Pricing trends 106
Market impact of biosimilars 108
Factors affecting biosimilar penetration 109
Interchangeability/substitution policies 109
Product differentiation 110
Marketing strategies 110
Competition 111
Chapter 7 Appendix 112
Primary research methodology 112
Glossary 118
Index 120
List of Figures
Figure 1.1: Product groups most affected by biosimilars by 2010 21
Figure 1.2: Major challenges faced by biosimilar companies 28
Figure 3.3: Markets with highest potential for biosimilar penetration 50
Figure 3.4: Development of Chinese biopharmaceutical market, 2001-2006 53
Figure 4.5: Types of partnerships favored by biosimilar companies 83
Figure 5.6: Global EPO market 92
Figure 5.7: Global G-CSF market 95
Figure 6.8: Price differential between original brand and biosimilar 107
Figure 6.9: Penetration of biosimilars in biotech market by 2010 108
List of Tables
Table 1.1: Sales trends of leading biologics by product category, 2006 20
Table 1.2: Patent status of key categories 22
Table 1.3: Marketed biosimilars by product group 22
Table 1.4: Summary of leading companies' biosimilar projects 25
Table 4.5: Teva's biosimilar products 70
Table 4.6: Stada's geographical sales distribution 76
Table 6.7: Selected target products for biosimilar developers 105

[ Home ] [ Contact ] [ Site Map ]
© UBIQUICK SARL tous droits réservés